Tag: Dr. Reddy

While Dr. Reddy’s will exclusively manage private-market distribution, disease awareness, and healthcare professional engagement, Takeda will retain rights for the public market, legal ownership, and overall medical and brand oversight. File | Photo Credit: Reuters Dr. Reddy’s Laboratories on Friday (September 18, 2026) entered into an exclusive distribution agreement with Takeda Pharmaceutical Company to promote…

Read More “Dr. Reddy’s, Takeda Pharma ink pact to distribute India’s first dengue vaccine QDENGA” »

Dr. Reddy’s Laboratories on Tuesday said it is foraying into the biosimilar immuno-oncology therapy segment in India with the launch of Nivorz, a biosimilar of Bristol Myers Squibb’s Opdivo (nivolumab). The biosimilar has been developed and manufactured entirely in-house at its biologics facility in Bachupally, Hyderabad. The launch reflects the company’s end-to-end capabilities across the…

Read More “Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz” »

Dr. Reddy’s Labs | Photo Credit: The Hindu Contract research, development and manufacturing organisation Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy’s Laboratories, has entered into a long-term manufacturing and supply agreement (MSA) with a leading global pharmaceutical company. Under the agreement, Aurigene will undertake commercial drug-product manufacturing and supply for a diversified portfolio targeting…

Read More “Dr. Reddy’s CDMO arm Aurigene inks long-term manufacturing pact with global pharma major” »

Dr. Reddy’s Laboratories has ended its more than four-year relationship with Novartis India, terminating an agreement under which it distributed and promoted select brands of the Swiss drugmaker in India. The termination of the February 11, 2022, agreement follows a change in the controlling shareholding of Novartis India. It will continue to commercialise the brands…

Read More “Dr. Reddy’s, Novartis India terminate agreement” »

A view of Dr. Reddy’s Lab facility near Hyderabad. | Photo Credit: The Hindu Dr. Reddy’s Laboratories has been issued three observations by the U.S. Food and Drug Administration (U.S. FDA) after an inspection of its facility in Srikakulam, Andhra Pradesh. The U.S. FDA has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP)…

Read More “Dr. Reddy’s Srikakulam facility gets 3 U.S. FDA observations” »